For AI assistants & researchers — machine-readable summary of this page
What this page is: Delvantic's full research page for Becton, Dickinson and Company (BDX) — AI-driven forensic equity research: mechanical valuation models (DCF, EPV, anchored-PE, scenario) plus three independent AI lenses (Quality / Value / Sentiment). Everything below is rendered server-side; you are not missing content that requires JavaScript. All scores are predictions and research opinions, not financial advice.
Our current read (analysis of 2026-08-23): Designation Low · Gem Score -39 (−100…+100 Quality+Value blend) · Quality 1 · Value -72 · Sentiment -15 (timing only, not weighted) · Composite fair value $97.03 vs $183.40 at analysis
Page map (sections in order; each card carries a stable
reference-name attribute you can cite):
profile-header/price-overview— company profile, live quote, market capextended-analysis— the core: three AI lens reads with findings, scores, and the analyst memofuture-predictions— our forward price-band predictionsmarket-narrative/ai-findings/gpt-critique— narrative context, cross-model findings, and an adversarial critique of our own analysis (near the end of the document)- Members-only sections (render as login gates for anonymous readers):
price-history,income-trend,key-metrics,financials(statement tables),insider-trading. The analysis above is public; the raw data tables require a free account.
More for machine readers: site briefing at
/llms.txt ·
any ticker resolves at delvantic.com/stock/TICKER ·
raw inputs are public-company filings and market data (via licensed data feeds);
every model, score, lens read, and prediction on this page is Delvantic's own analysis.
Becton, Dickinson and Company
BDX NYSEBecton, Dickinson and Company is a global medical technology company that develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare systems and research institutions worldwide. Its portfolio includes medical surgical products such as needles, syringes, and sharps-disposal units, as well as prefilled drug delivery systems that support medication administration in clinical and home-care settings. In diagnostics and life sciences, the company provides instruments, reagents, and systems used for specimen collection, infectious disease testing, and advanced cell analysis, including flow cytometry and cell-imaging platforms. Becton, Dickinson and Company operates through distinct business segments that address medication management, life science research, and interventional therapies, serving hospitals, clinics, laboratories, and biopharmaceutical companies. Headquartered in Franklin Lakes, New Jersey, and founded in 1897, it plays a significant role in supporting healthcare delivery and laboratory workflows across both developed and emerging markets.
Price Overview
Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): 5.82
Total Equity: $25.39B
Shares: 288,509,000
Total Debt: $19.18B
Cash: $641.00M
EBITDA: $5.04B
Total Debt: $19.18B
Cash: $641.00M
Revenue: $21.84B
Revenue: $21.84B
Revenue: $21.84B
Total Equity: $25.39B
Tax Rate: 10.8%
Equity: $25.39B
Total Debt: $19.18B
Cash: $641.00M
Current Liabilities: $8.31B
Long-Term Debt: $17.62B
Total Debt: $19.18B
Total Equity: $25.39B
Shares: 288,509,000
Shares: 288,509,000
CapEx: -$760.00M
Shares: 288,509,000
Stock Price: $183.40
Net Income: $1.68B
Industry Benchmarks
Income Statement (Annual)
Last updated: Aug 17, 2026 12:40am (6d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $20.2B | $18.9B | $19.4B | $20.2B | $21.8B |
| Cost of Revenue | $10.8B | $10.4B | $11.2B | $11.1B | $11.9B |
| Gross Profit | $9.4B | $8.5B | $8.2B | $9.1B | $9.9B |
| Operating Expenses | $6.6B | $6.2B | $6.1B | $6.7B | $7.3B |
| Operating Income | $2.8B | $2.3B | $2.1B | $2.4B | $2.6B |
| Net Income | $2.1B | $1.8B | $1.5B | $1.7B | $1.7B |
| EBITDA | $5.1B | $4.5B | $4.4B | $4.7B | $5.0B |
| EPS | $6.92 | $5.93 | $4.97 | $5.88 | $5.83 |
| EPS (Diluted) | $6.85 | $5.88 | $4.94 | $5.86 | $5.82 |
Balance Sheet (Annual)
Last updated: Aug 17, 2026 12:22am (6d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $2.3B | $1.0B | $1.4B | $1.7B | $641.0M |
| Total Current Assets | $8.8B | $8.1B | $8.7B | $10.5B | $9.3B |
| Total Assets | $53.9B | $52.9B | $52.8B | $57.3B | $55.3B |
| Current Liabilities | $6.6B | $7.8B | $6.6B | $9.0B | $8.3B |
| Long-Term Debt | $17.1B | $13.9B | $14.7B | $17.9B | $17.6B |
| Total Liabilities | $30.2B | $27.7B | $27.0B | $31.4B | $29.9B |
| Total Equity | $23.7B | $25.3B | $25.8B | $25.9B | $25.4B |
| Retained Earnings | $13.8B | $15.2B | $15.5B | $16.1B | $16.6B |
Cash Flow (Annual)
Last updated: Aug 17, 2026 12:40am (6d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $4.6B | — | — | — | — |
| Capital Expenditure | -$1.2B | -$973.0M | -$874.0M | -$725.0M | -$760.0M |
| Free Cash Flow | $3.4B | — | — | — | — |
| Acquisitions (net) | -$508.0M | -$2.1B | $0 | -$3.9B | $0 |
| Net Debt Issued / (Repaid) | -$243.0M | -$308.0M | -$493.0M | $3.4B | -$1.8B |
| Dividends Paid | -$1.0B | -$1.1B | -$1.1B | -$1.1B | -$1.2B |
| Stock Buybacks | -$1.8B | -$500.0M | $0 | -$500.0M | -$1.0B |
| Net Change in Cash | -$525.0M | -$1.2B | $322.0M | $375.0M | -$1.0B |
Growth Trends (YoY %)
Last updated: Aug 17, 2026 12:40am (6d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | -6.8% | +2.7% | +4.2% | +8.2% |
| Gross Profit Growth | -10.1% | -3.6% | +11.7% | +8.8% |
| Operating Income Growth | -18.5% | -7.5% | +13.5% | +7.6% |
| Net Income Growth | -15.0% | -16.6% | +14.9% | -1.6% |
| EBITDA Growth | -11.1% | -2.5% | +6.5% | +7.6% |
Dividend History (Last 20)
Last updated: Aug 12, 2026 10:13am (11d ago)| Date | Dividend | Declaration | Record | Payment |
|---|---|---|---|---|
| 2026-06-09 | $1.05 | — | — | — |
| 2026-03-10 | $1.05 | — | — | — |
| 2025-12-08 | $1.05 | — | — | — |
| 2025-09-08 | $1.04 | — | — | — |
| 2025-06-09 | $1.04 | — | — | — |
| 2025-03-10 | $1.04 | — | — | — |
| 2024-12-09 | $1.04 | — | — | — |
| 2024-09-09 | $0.95 | — | — | — |
| 2024-06-10 | $0.95 | — | — | — |
| 2024-03-07 | $0.95 | — | — | — |
| 2023-12-07 | $0.95 | — | — | — |
| 2023-09-07 | $0.91 | — | — | — |
| 2023-06-08 | $0.91 | — | — | — |
| 2023-03-09 | $0.91 | — | — | — |
| 2022-12-08 | $0.91 | — | — | — |
| 2022-09-08 | $0.87 | — | — | — |
| 2022-06-08 | $0.87 | — | — | — |
| 2022-03-09 | $0.85 | — | — | — |
| 2021-12-09 | $0.85 | — | — | — |
| 2021-09-08 | $0.81 | — | — | — |
Deep Analysis
Risk : Reward — if the last quarter repeats
Live · as of 2026-08-19 08:35Recovery pays +0%; another quarter like the worst recent one costs 86%. Ratio 0.0:1.
| Case | Growth | Margin | Fair value | vs price ($183.40) |
|---|---|---|---|---|
| Bull — recovery | +7% | 16.6% | $183.96 | +0% |
| Base — stabilizes | +5% | 14.4% | $147.94 | -19% |
| Bear — keeps slipping | +2% | 12.3% | $116.33 | -37% |
| Stress — last quarter repeats | +5% | 2.1% | $25.51 | -86% |
Narrative Economics
market-narrative step).
AI Lens 4th lens · how AI reaches this business · 5-yr
2026-08-17AI attacks the labor bottleneck inside BD's customers — microbiology plate reading, specimen handling, medication management — which makes BD's automation platforms (Kiestra, Pyxis, cytometry) easier to justify and pulls through more reagent and consumable volume.
BD's monetized units are largely commodity consumables bought through GPOs and distributors; as AI sharpens hospital procurement analytics and sourcing comparison, price transparency on needles, syringes and collection tubes tightens the exact line items where BD has least differentiation.
Whether AI-enabled savings in BD's own manufacturing, quality and SG&A base are retained or handed back in contract renegotiation — visible in gross margin breaking above the stubborn 45% band without mix help, and in SG&A as a percent of revenue.
Global sterile high-volume manufacturing at cents-per-unit cost, thousands of FDA/CE clearances and validated instrument-reagent pairings, and hospital-embedded installed base with GPO contracts — none of which cheap software creates.
AI Lens thesis
The need (safe fluid transfer, specimen collection, medication delivery, infection diagnosis) is physical and permanent, and the revenue unit is a disposable consumed per patient, so AI cannot dematerialize the product. AI reaches BDX through three narrow channels: it raises willingness to buy lab and pharmacy automation because clinical labor is scarce and getting scarcer; it can compress BD's own cost of quality, complaint handling, regulatory documentation and back office across a ~$22B revenue base where operating margin has sat near 12%; and it modestly strengthens buyer-side leverage on commoditized consumables. The software layer BD sells around instruments is the most reproducible part of the portfolio, but it is bolted to razor-blade reagent economics that survive commoditized intelligence. Net: exposure is genuinely low, direction mildly positive, and the fallen-angel debate is decided by integration execution and litigation, not by AI.
What the market may be underestimating
Upside AI-assisted care shifting infusion and biologic administration into the home raises demand for prefillable syringes, autoinjectors and safety devices — a BD-advantaged, clearance-heavy niche software entrants cannot serve.
Downside AI-driven lab consolidation means fewer, larger, better-informed diagnostics buyers; the same automation that sells instruments can shrink the number of sites BD sells them to and hand the survivors real pricing power over reagents.
Outcome range spread 33
Growth Outlook
Analyzed 2026-08-17 16:13The question every valuation on this page silently assumes: is this company likely to grow? Judged forward — the business, its category, the world — against what's already printed.
Claude Reading
The raw numbers tell a messier story than "mature earner" suggests. TTM revenue reconstructed from the quarterlies is roughly $22.4B, but the quarterly cadence is bizarre — a $7.47B Q4-2025 spike sandwiched between $4.5-5.3B prints, plus a $311M net loss in March 2026. That kind of volatility in a "syringes and needles" business signals either significant restructuring/divestiture accounting (BD spun off its Biosciences/Diagnostic Solutions unit to Waters in 2025) or non-recurring charges that make the reported P/E of 31.5x nearly meaningless. Normalized net income on ~$21.8B annual revenue is $1.68B — a 7.7% net margin that has been flat-to-declining for five years (2021 NI was $2.09B on $20.25B rev, so earnings have actually gone *backwards* in absolute terms while share count is roughly flat). ROIC of 5.2% against a debt load of $19.2B and only $641M cash is the real story: this company is not earning its cost of capital.
I largely agree with the synthesis verdict but think the $85 fair value anchor is generous, not conservative. At 15x normalized $1.7B earnings you get $25.5B equity value, or roughly $89/share — and that's before haircutting for the fact that earnings haven't grown in real terms since 2021, ROIC is sub-WACC, and the balance sheet carries 0.76x debt/equity with a 71% payout ratio that leaves almost no room for deleveraging or reinvestment. The Market Forces "structural impairment" call is more aggressive than the data warrants — GLP-1 disruption to BD's diabetes care franchise is real but is one segment among many, and syringe/needle demand isn't going to zero. But the fallen-angel narrative from the Narrative layer is directionally correct: this is post-Bard-acquisition value destruction dressed up as "temporary headwinds," and the market is still paying 2.1x DCF for the mythology.
The contrarian case: BD's medical consumables are genuinely non-substitutable, the Waters spinoff (closing 2026) removes a low-growth diagnostics drag and could unlock a re-rating, and at current levels the 2.04% dividend yield with a covered (if tight) payout provides some floor. If you believe the March 2026 loss was spinoff-related noise and normalized EPS run-rates toward $6.50-7.00 post-separation, then 20x gets you to $130-140 — still well below $183 but not the $85 disaster case. The insider activity is genuinely neutral-to-mildly-negative (small sales, routine awards, one 20K option exercise) — nothing here suggests management sees a bargain at these prices, which is itself informative for a mature company where insiders should know the normalized earnings power.
Where the models are thin: nobody has properly adjusted for the Waters spinoff, which materially changes the revenue base, margin profile, and comparable multiples going forward — the TTM numbers are essentially uninvestable as-is. The "revenue CAGR 6.2%" is flattered by acquisition accounting; organic growth is closer to 3-4%. Free cash flow isn't disclosed in this file, which is a gaping hole for a levered mature business — you cannot evaluate BDX without OCF and FCF conversion, and the fact that capex is -$760M against $1.68B NI suggests FCF is probably $1.5-2B, implying a 3-4% FCF yield at current price. That's not a value stock; that's a bond-proxy priced when rates were zero. I dissent slightly from synthesis on magnitude — fair value is more like $115-130 accounting for a possible post-spinoff re-rating, not $85 — but agree fully on direction. Overvalued, and the setup for a disappointing print or guide-down is the most likely catalyst to close the gap.
GPT Reading
What stands out first is that BDX is not a broken business, but it is absolutely a low-return business being valued like a higher-quality medtech compounder. Revenue has recovered respectably: from $20.18B in FY24 to $21.84B in FY25, up 8.2%, and the quarterly run-rate since then is still positive, with June 2026 revenue of $4.98B versus $4.73B a year earlier, about 5.3% growth. Gross margin also improved to 45.4% in FY25 from 45.2%-ish levels implied in prior years, and operating income rose to $2.58B from $2.40B. So the top-line story is fine. The issue is that this growth is not flowing through cleanly to shareholder economics. FY25 net income was $1.68B, still below FY21’s $2.09B despite higher sales today, and ROIC is only 5.2% with ROE 6.6%. For a company carrying $19.18B of debt against just $641M of cash, that is not a premium-quality return profile.
The quarter-to-quarter earnings pattern reinforces that concern. Over the last four reported quarters, revenue sums to roughly $22.4B, which suggests the business is still growing modestly, but net income over those same four quarters is only about $941M because one quarter swung to a $311M loss. Even if I normalize that loss away as non-recurring, the “normal” quarterly margin still looks more like 7%-8% than the 10%+ a stock at 31.5x earnings should command. FY25 operating margin was 11.8%, up from 11.9%? No, basically flat versus the last few years and well below the 13.8% delivered in FY21. That is the core mismatch with the price: investors are paying 2.4x sales and 14.1x EBITDA for a company whose margins and returns have not recovered to prior levels despite a favorable base of recurring, essential products. This is a stable franchise, but stability alone does not justify paying up when earnings quality is this uneven.
I also do not buy the most dramatic bearish framing that the business is structurally collapsing. The numbers do not support that. Annual revenue has risen from $18.87B in FY22 to $21.84B in FY25, gross profit from $8.48B to $9.93B, and operating income from $2.28B to $2.58B. That is not commoditization-driven decay. The current ratio at 1.11 is not great, but it is serviceable for a mature medtech operator, and the debt-to-equity ratio of 0.76 is elevated rather than existential. If anything, the real problem is mediocrity: decent growth, decent margins, weak net conversion, and leverage that limits strategic flexibility. At $183, the market is valuing BDX more like a defensive quality asset than a merely acceptable one. On the numbers here, a more reasonable framing is a mid-teens earnings multiple on normalized earnings power, not 31x reported EPS.
The strongest case against my view is that reported earnings are likely understating true earning power because of litigation, restructuring, amortization, and other episodic charges that hit GAAP but not the long-run cash engine. That case has some support in the data: revenue is growing, gross margins are healthy at 45.4%, operating income is inching up, and the business has enough installed-base stickiness that a bad quarter does not mean franchise erosion. If normalized net income is closer to, say, $2.2B-$2.5B rather than the reported $1.68B, then today’s valuation compresses meaningfully and BDX starts to look closer to fair value, especially for investors willing to pay a premium for resilience and a 2.0% dividend yield. I weigh that argument less heavily because the burden of proof is now on management to show that “temporary” below-the-line drags are truly temporary. When FY25 revenue is above FY21 by roughly $1.6B but net income is lower by over $400M, I need more than an adjustment narrative.
What would change my mind is straightforward. If BDX can produce two or three consecutive quarters with revenue growth still in the 5%-6% range and net margins back above 10%, the current price would become much easier to defend. Concretely, I would want to see quarterly net income sustain at least $500M-$550M on a roughly $5.0B revenue base, implying annualized earnings power above $2.0B without a loss quarter interrupting the story. I would also want evidence of deleveraging or materially better cash conversion, because $19.18B of debt is much easier to tolerate if free cash flow is visibly covering it. Without that, I think the stock remains priced for a cleaner recovery than the reported economics justify.
Grok Reading
The numbers on BDX describe a mature, low-return medical-supplies franchise that the market is still treating like a growth compounder. Fiscal 2025 revenue of $21.84B is only modestly above the $20.25B printed in 2021, a five-year stretch that nets out to low-single-digit growth even after the Bard integration years; net income has gone the wrong way, from $2.09B to $1.68B, and trailing ROE and ROIC sit at a soft 6.6% and 5.2%. Quarterly progression is choppy rather than accelerating: the June 2026 quarter delivered $4.98B and a 7.6% net margin, but March printed a $311M loss, and the outsized $7.47B September 2025 print looks like a calendar or one-time bulge rather than a new run-rate. Gross margin holds near 45%, yet operating margin has compressed to roughly 11.8% and net margin to 7.7%—nowhere near enough operating leverage to justify a 31.5x earnings multiple or a 14.1x EV/EBITDA on a business growing mid-single digits at best. The balance sheet compounds the problem: $19.18B of debt against only $641M of cash and a current ratio of 1.11 leaves little cushion, while a 71% payout ratio on a 2.0% yield means the dividend is consuming most of what the firm earns. At $183 the stock is pricing a durable margin recovery and ROIC expansion that the last five years of reported results simply have not delivered.
What stands out most is the gap between the valuation synthesis fair-value band ($85–$97) and the tape. Even granting the pre-flight thesis that Interventional could lift organic growth from ~3–4% toward mid-single digits, the implied multiple still requires either a structural re-rating of the entire consumables base or a sharp rebound in free-cash-flow conversion that the incomplete cash-flow disclosure does not support. Recent revenue year-over-year of +8.2% looks better than the multi-year CAGR, but earnings are already slipping (-1.6% YoY) and the March loss quarter shows how quickly litigation, mix, or one-time items can erase a half-year of progress. Insider activity is noise—routine awards and small sales—not a signal. Against peers the stock is lagging, and the “essential infrastructure” narrative is doing heavy lifting that the returns on capital do not corroborate.
The strongest opposing case is straightforward: BD remains a scaled, regulated, recurring-revenue franchise with hospital and government stickiness that is hard to displace, a 130-year operating history, and a dividend that income-oriented healthcare funds will continue to own through the trough. Bulls can point to the 6.2% revenue CAGR, the fact that fiscal 2025 revenue did grow 8% year-over-year to $21.84B, operating income still positive at $2.58B, and the argument that opioid-related and integration drags are genuinely transitory; if those clear, margin could re-expand toward the 12%+ net prints seen in isolated quarters and the 31x multiple would look less extreme on forward earnings. EV/revenue of 3.3x is not outrageous for medtech with a consumables moat, and a fallen-angel re-rating has happened before in this sector once litigation overhangs lift. I weigh that less heavily because ROIC at 5% does not clear a reasonable cost of capital, net debt is elevated enough to constrain flexibility, and five years of flat-to-down earnings already tested the “temporary trough” story without producing the multiple compression that fundamentals would imply—suggesting the premium is sticky for narrative reasons, not cash-flow ones.
I would flip if the next two reported quarters show sequential operating-margin expansion back above 13–14% with clean net income above $500M, if management deleverages toward a sub-0.5 debt-to-equity ratio while holding the dividend, or if organic growth sustains above 6% for three consecutive quarters without one-time revenue spikes. Absent that, the $183 price remains a rich entry for a mid-single-digit grower with sub-par returns on capital.
Big-3 Panel — where each AI stands
Advanced Analysis Forensic deep-dive · separate lenses
BDX is a scale player in medical instruments and supplies, running roughly 45% gross margins and ~12% operating margins on $21.8B of 2025 revenue. Revenue has compounded modestly from $20.25B (2021) to $21.84B (2025), with net income drifting sideways in the $1.48-2.09B band. Earnings quality on the mechanical checks is clean: OCF/NI at 1.93x, accruals -3% of assets, Beneish M at -2.63. Share count is essentially flat (diluted CAGR -0.3%) with buybacks running 3x SBC, so per-share value is not being leaked.
Verify before trusting this (5)
- Reconcile the negative FCF: is it capex intensity, working-capital build, or acquisition/integration outflows in the cash flow statement?
- Absolute debt levels, maturity ladder, and interest coverage behind the 1.99 Altman Z.
- Segment mix and any customer or geographic concentration inside the $21.8B revenue base.
- Whether the 2022-2023 margin compression was tied to a specific acquisition (e.g., spin/integration) or broader cost inflation.
- Recent guidance and any restructuring or divestiture actions that could normalize FCF.
The e2e composite pins fair value at $97.03 and the signal-adjusted FV at $84.90, with EPV floor $91.13 and anchored-PE $102.92 - a tight cluster in the $85-103 band vs a $183.40 print. Even giving the business full credit as a Solid, essential-infrastructure franchise, that is a roughly 45-55% premium to deserved value, and the Company-Quality lens flags four straight years of negative reported FCF against sideways net income - exactly the pattern that should compress, not expand, the multiple. Earnings quality is high (score 2), so I am not haircutting further, but I am also not adding a quality premium on top of a business that is not currently gushing cash.
Verify before trusting this (4)
- FCF conversion trajectory in the next 2-3 quarters - is the negative FCF run actually ending
- Segment-level margin recovery post-Bard integration and any one-time integration/restructuring charges still flowing through
- Guidance on capex intensity and working capital - the swing factors that would rehabilitate the EPV/DCF inputs
- Any signs of accelerating organic growth above mid-single digits that would justify a higher anchored PE
BDX sits in an awkward sentiment pocket. The tape is mildly risk-on (VIX 14, S&P near highs), but with a beta of 0.26 essentially none of that animal spirit transmits to this name - defensive medtech is exactly the cohort that gets left behind when money is chasing higher-octane stories. So the macro tailwind that would juice a high-beta growth name barely brushes BDX. Meanwhile the active narrative is fallen-angel with moderate intensity and only moderate durability, low cult - meaning the market is neither excited about a turnaround nor panicked enough to capitulate. That's a story stuck in neutral. The recent tape supports the neutral read: a solid Q3 beat plus raised guidance drove a +3.8% pop on Aug 6, and a dividend hike lifted it 4.7% on Jul 28 - both classic defensive-quality signals that landed cleanly but did not spark a re-rating. Working against BDX is the contrast with peer West Pharma ripping +38% on a GLP-1 / HVP narrative; that's a reminder that capital in medtech is rotating toward stories, and BDX has none. Net: no meaningful push either way, with a slight negative tilt from narrative absence and rising D/E chatter, offset by defensive bid and recent operational wins.
Verify before trusting this (4)
- Whether analyst target revisions post-Q3 beat skew positive or stay flat - a re-rating signal
- Any GLP-1, diagnostics, or portfolio-reshaping announcement that could hand BDX its own narrative
- Litigation headlines - a settlement clarity moment would remove the fallen-angel overhang
- Sector rotation - if defensives catch a bid on any VIX spike, BDX would be a prime beneficiary
The need (safe fluid transfer, specimen collection, medication delivery, infection diagnosis) is physical and permanent, and the revenue unit is a disposable consumed per patient, so AI cannot dematerialize the product. AI reaches BDX through three narrow channels: it raises willingness to buy lab and pharmacy automation because clinical labor is scarce and getting scarcer; it can compress BD's own cost of quality, complaint handling, regulatory documentation and back office across a ~$22B revenue base where operating margin has sat near 12%; and it modestly strengthens buyer-side leverage on commoditized consumables. The software layer BD sells around instruments is the most reproducible part of the portfolio, but it is bolted to razor-blade reagent economics that survive commoditized intelligence. Net: exposure is genuinely low, direction mildly positive, and the fallen-angel debate is decided by integration execution and litigation, not by AI.
None surfaced.
Verify before trusting this (8)
- procedure and hospital admission volumes
- biologic injectable launch pipeline
- home-infusion site-of-care shift
- unit volume vs price contribution
- test volume in diagnostics
- prefilled device unit growth
- reagent attach rate per instrument
- third-party software on BD instruments
Demand is demographic and procedural, not discretionary: aging populations, rising procedure counts and the shift of biologics to self-injection all pull consumable and delivery-device volume forward regardless of the cycle. Against that, the payer side of the world is tightening — hospital budget scrutiny, Chinese procurement price resets and constrained public research funding compress the equipment and reagent end of the portfolio. Net: the volume backdrop supports mid-single-digit revenue for years; the price/mix backdrop is where the erosion happens, which is exactly why revenue can grow while earnings sit flat.
When we made this prediction on Aug 17, 2026, BDX was $183.40. We expect it to be $168.50 by Feb 2027, and we consider it great value under $110.00. This is an early model (v0.6.0) — the direction is more reliable than the exact price. Made Aug 17, 2026.
Blue is our prediction, starting the day we made it. Grey is a slower route to the same place — the same destination, taking longer. Black is the actual price, so you can see how we are doing.